Cargando…
KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244430/ https://www.ncbi.nlm.nih.gov/pubmed/22216189 http://dx.doi.org/10.1371/journal.pone.0029146 |
_version_ | 1782219730373836800 |
---|---|
author | Normanno, Nicola Pinto, Carmine Castiglione, Francesca Bardelli, Alberto Gambacorta, Marcello Botti, Gerardo Nappi, Oscar Siena, Salvatore Ciardiello, Fortunato Taddei, GianLuigi Marchetti, Antonio |
author_facet | Normanno, Nicola Pinto, Carmine Castiglione, Francesca Bardelli, Alberto Gambacorta, Marcello Botti, Gerardo Nappi, Oscar Siena, Salvatore Ciardiello, Fortunato Taddei, GianLuigi Marchetti, Antonio |
author_sort | Normanno, Nicola |
collection | PubMed |
description | BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate therapy for these patients. METHODOLOGY/PRINCIPAL FINDINGS: In order to guarantee the possibility for mCRC patients to receive an high quality KRAS testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology -Italian division of the International Academy of Pathology (SIAPEC-IAP) started a program to improve KRAS testing. AIOM and SIAPEC identified a large panel of Italian medical oncologists, pathologists and molecular biologists that outlined guidelines for KRAS testing in mCRC patients. These guidelines include specific information on the target patient population, the biological material for molecular analysis, the extraction of DNA, and the methods for the mutational analysis that are summarized in this paper. Following the publication of the guidelines, the scientific societies started an external quality assessment scheme for KRAS testing. Five CRC specimens with known KRAS mutation status were sent to the 59 centers that participated to the program. The samples were validated by three referral laboratories. The participating laboratories were allowed to use their own preferred method for DNA extraction and mutational analysis and were asked to report the results within 4 weeks. The limit to pass the quality assessment was set at 100% of true responses. In the first round, only two centers did not pass (3%). The two centers were offered to participate to a second round and both centers failed again to pass. CONCLUSIONS: The results of this first Italian quality assessment for KRAS testing suggest that KRAS mutational analysis is performed with good quality in the majority of Italian centers. |
format | Online Article Text |
id | pubmed-3244430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-32444302012-01-03 KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment Normanno, Nicola Pinto, Carmine Castiglione, Francesca Bardelli, Alberto Gambacorta, Marcello Botti, Gerardo Nappi, Oscar Siena, Salvatore Ciardiello, Fortunato Taddei, GianLuigi Marchetti, Antonio PLoS One Research Article BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate therapy for these patients. METHODOLOGY/PRINCIPAL FINDINGS: In order to guarantee the possibility for mCRC patients to receive an high quality KRAS testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology -Italian division of the International Academy of Pathology (SIAPEC-IAP) started a program to improve KRAS testing. AIOM and SIAPEC identified a large panel of Italian medical oncologists, pathologists and molecular biologists that outlined guidelines for KRAS testing in mCRC patients. These guidelines include specific information on the target patient population, the biological material for molecular analysis, the extraction of DNA, and the methods for the mutational analysis that are summarized in this paper. Following the publication of the guidelines, the scientific societies started an external quality assessment scheme for KRAS testing. Five CRC specimens with known KRAS mutation status were sent to the 59 centers that participated to the program. The samples were validated by three referral laboratories. The participating laboratories were allowed to use their own preferred method for DNA extraction and mutational analysis and were asked to report the results within 4 weeks. The limit to pass the quality assessment was set at 100% of true responses. In the first round, only two centers did not pass (3%). The two centers were offered to participate to a second round and both centers failed again to pass. CONCLUSIONS: The results of this first Italian quality assessment for KRAS testing suggest that KRAS mutational analysis is performed with good quality in the majority of Italian centers. Public Library of Science 2011-12-21 /pmc/articles/PMC3244430/ /pubmed/22216189 http://dx.doi.org/10.1371/journal.pone.0029146 Text en Normanno et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Normanno, Nicola Pinto, Carmine Castiglione, Francesca Bardelli, Alberto Gambacorta, Marcello Botti, Gerardo Nappi, Oscar Siena, Salvatore Ciardiello, Fortunato Taddei, GianLuigi Marchetti, Antonio KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment |
title | KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment |
title_full | KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment |
title_fullStr | KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment |
title_full_unstemmed | KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment |
title_short | KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment |
title_sort | kras mutations testing in colorectal carcinoma patients in italy: from guidelines to external quality assessment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244430/ https://www.ncbi.nlm.nih.gov/pubmed/22216189 http://dx.doi.org/10.1371/journal.pone.0029146 |
work_keys_str_mv | AT normannonicola krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT pintocarmine krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT castiglionefrancesca krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT bardellialberto krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT gambacortamarcello krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT bottigerardo krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT nappioscar krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT sienasalvatore krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT ciardiellofortunato krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT taddeigianluigi krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment AT marchettiantonio krasmutationstestingincolorectalcarcinomapatientsinitalyfromguidelinestoexternalqualityassessment |